Savara to Participate in Two Upcoming Investor Healthcare Conferences
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
H.C. Wainwright23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET/ 4:00 AM PTon September 13, 2021.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of the presentation will take place at
12:25 PM ET/ 9:25 AM PTon September 20, 2021.
Both webcast presentations will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (